Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTOPIA Phase 3 study of UGN-103 in intermediate-risk low-grade nonmuscle invasive bladder cancer
2023-507261-25-00Phase 3Completed
- Sponsor
- UroGen Pharma
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of UGN-103 in non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Primary endpoint: Complete response rate at 3 months. Started Oct 2024; status: completed.
02
Drugs
UGN-103
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2023-507261-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507261-25-00.